Zymeworks (ZYME) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Zymeworks Inc., a biotech firm advancing novel biotherapeutics for challenging diseases, has announced its participation in upcoming investor conferences, including a virtual event on August 6 and a panel discussion in New York on August 14. The company is known for its HER2-targeted bispecific antibody zanidatamab, which is under Priority Review by the FDA for the treatment of HER2-positive biliary tract cancer.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
